EQL Pharma (EQL) Aktievy
EQL Pharma AB (publ) bedriver utveckling, marknadsföring och försäljning av generiska läkemedel till apotek och sjukhus i Sverige, Danmark, Norge, Finland och övriga Europa. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 6/6 |
| Tidigare resultat | 2/6 |
| Finansiell hälsa | 2/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
EQL Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
SEK 86.37
FV
76.4% undervärderad intrinsisk rabatt21.49%
Revenue growth p.a.
163
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
EQL Pharma AB (publ) Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | SEK 20.35 |
| 52 veckors högsta | SEK 96.80 |
| 52 veckors lägsta | SEK 19.20 |
| Beta | 0.25 |
| 1 månads förändring | -14.14% |
| 3 månaders förändring | -59.14% |
| 1 års förändring | -77.86% |
| 3 års förändring | -27.84% |
| 5 års förändring | -44.09% |
| Förändring sedan börsintroduktionen | 250.86% |
Senaste nyheter och uppdateringar
Recent updates
Uppdatering av berättelse • Jun 17
EQL: European Rollout And New UTI Therapy Will Drive Future Upside
Analysts have kept their SEK price target for EQL Pharma broadly unchanged, with only minimal adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E. This reflects a largely steady view of the stock's valuation profile.Uppdatering av berättelse • Jun 02
EQL: European Rollout And Supply Chain Improvements Will Drive Future Upside
Analysts have reduced their fair value estimate for EQL Pharma’s shares from SEK 75 to SEK 50, citing updates to their models that reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News EQL Pharma issued earnings guidance for 2026/27, with sales growth below its long term 30% target and an EBITDA margin of 10%, reflecting impacts from supply shortages and one off effects.Analysartikel • May 14
This Analyst Just Downgraded Their EQL Pharma AB (publ) (STO:EQL) EPS Forecasts
The analyst covering EQL Pharma AB (publ) ( STO:EQL ) delivered a dose of negativity to shareholders today, by making a...Analysartikel • May 13
EQL Pharma AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
There's been a major selloff in EQL Pharma AB (publ) ( STO:EQL ) shares in the week since it released its yearly...Uppdatering av berättelse • Apr 23
EQL: Italian Approval And New Market Entry Will Support Future Upside Potential
Analysts have adjusted their price target on EQL Pharma to SEK 75 from SEK 80, citing updated assumptions for revenue growth, profit margins and future P/E. These changes point to a slightly more conservative outlook on the shares.Uppdatering av berättelse • Apr 09
EQL: Italian Market Entry And Steady Assumptions Will Support Future Upside Potential
Analysts have maintained their SEK price target for EQL Pharma at SEK 80.00, citing consistent assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News EQL's key product Mellozzan, which contains melatonin, has received Marketing Authorization approval from the Italian medicines agency AIFA for use in Italy, through licensing partner Italfarmaco S.p.A. (Key Developments) Mellozzan is indicated for children with ADHD who have sleep difficulties where sleep hygiene measures have not worked, and for short term treatment of jet lag in adults.Uppdatering av berättelse • Mar 26
EQL: Long Term Incentive Program Will Support Strong Future Upside Potential
Analysts keep their SEK 80.00 fair value estimate for EQL Pharma unchanged, reflecting steady assumptions on discount rate, revenue growth, profit margin and future P/E, with no new Street research prompting a shift in the target. What's in the News A special or extraordinary shareholders meeting is scheduled for February 3, 2026, at 13:00 W.Uppdatering av berättelse • Mar 11
EQL: Long Term Incentive Program Will Support Strong Future Upside Potential
Analysts have kept their price target for EQL Pharma steady at SEK 80. This reflects unchanged views on fair value, discount rate, growth and margin assumptions.Uppdatering av berättelse • Feb 24
EQL: Leadership Restructuring And Incentive Plan Will Support Long Term Outlook
Analysts have kept their SEK price target for EQL Pharma unchanged at SEK 80. This reflects stable assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E.Uppdatering av berättelse • Feb 10
EQL: German UTI Prophylaxis Approval Will Support Stronger Long Term Outlook
Analysts have kept their fair value estimate for EQL Pharma unchanged at SEK 80.00. They explain the steady target by slightly different views on discount rate, revenue growth, profit margin and future P/E assumptions rather than any single strong new data point.Uppdatering av berättelse • Jan 27
EQL: German UTI Prophylaxis Launch Will Support Bullish Outlook
Analysts have kept their fair value estimate for EQL Pharma unchanged at SEK 80.00 per share, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E. What's in the News EQL Pharma has called a special or extraordinary shareholders meeting for February 3, 2026, at 13:00 W.Uppdatering av berättelse • Jan 12
EQL: Future UTI Prophylaxis Launch In Germany Will Drive Upside
Analysts have maintained their price target on EQL Pharma at SEK 80.00, citing consistent assumptions for the discount rate, revenue growth, profit margin and future P/E that support keeping the previous fair value assessment unchanged. What's in the News EQL Pharma has called a special/extraordinary shareholders meeting for February 3, 2026, at 13:00 W.Uppdatering av berättelse • Dec 23
EQL: Future UTI Prophylaxis Launch Will Drive Strong Upside Potential
Analysts have modestly adjusted their price target on EQL Pharma upward to SEK 80.0 per share from SEK 80.0 per share, citing unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples that continue to support the company’s current fair value assessment. What's in the News EQL Pharma strengthens and reorganizes its finance function, appointing Allan Sylvest Aasberg as new CFO from early April 2026, while current CFO Anna Jönsson becomes Head of Accounting (Key Developments) The new CFO is tasked with optimizing profitability, capital allocation, forecasting, and parts of investor relations to support a more scalable growth platform (Key Developments) Key product methenamine hippurate receives marketing approval in Germany under the EQL brand Cystohipp, the only registered product of its kind in that market, with launch planned for mid 2026 (Key Developments) Cystohipp targets recurrent urinary tract infections as a non antibiotic prophylactic option, addressing growing demand for alternatives that do not drive antibiotic resistance (Key Developments) EQL issues guidance indicating robust top line expansion, forecasting around 30 percent sales growth for 2024/25 and around 15 percent for 2025/26 (Key Developments) Valuation Changes Fair Value: unchanged at SEK 80.0 per share, indicating no revision to the overall equity valuation.Uppdatering av berättelse • Dec 09
EQL: New Non-Antibiotic UTI Therapy Will Drive Future Upside
Narrative Update on EQL Pharma Analysts have maintained their price target for EQL Pharma at SEK 80.00. This reflects unchanged assumptions on revenue growth, profitability, and valuation multiples despite recent model refinements.Uppdatering av berättelse • Nov 25
EQL: Expanding Market Approvals And New Launches Will Drive Future Upside
Analysts have maintained their price target for EQL Pharma at SEK 80.00. They cite stable fair value estimates supported by slightly improved projections for revenue growth and profit margin.Analysartikel • Nov 15
EQL Pharma's (STO:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Last week's earnings announcement from EQL Pharma AB (publ) ( STO:EQL ) was disappointing to investors, with a sluggish...Uppdatering av berättelse • Nov 06
EQL: Expansion Into New Markets Will Drive Upside In Coming Years
Analysts have lowered their price target for EQL Pharma from SEK 90.00 to SEK 80.00. They cite revised expectations for valuation and a slightly higher discount rate, despite improved forecasts for revenue growth and profit margin.Analysartikel • Oct 08
EQL Pharma AB (publ) (STO:EQL) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
EQL Pharma AB (publ) ( STO:EQL ) shareholders that were waiting for something to happen have been dealt a blow with a...Analysartikel • Sep 27
Do EQL Pharma's (STO:EQL) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysartikel • Sep 09
Capital Allocation Trends At EQL Pharma (STO:EQL) Aren't Ideal
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
Uppdatering av berättelse • Aug 16
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
2025 Q2 update Solid report. Revenue growth in line with expectations.Analysartikel • May 16
EQL Pharma's (STO:EQL) Earnings Are Of Questionable Quality
EQL Pharma AB (publ) ( STO:EQL ) just reported some strong earnings, and the market reacted accordingly with a healthy...Ny berättelse • May 11
Pipeline Launches And Global Expansion Will Drive Future Success
Strategic expansions and acquisitions, including Medilink and non-European market entry, are poised to drive significant revenue and profitability growth.Analysartikel • Mar 12
Here's Why EQL Pharma (STO:EQL) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Ny berättelse • Feb 22
EQL Pharma aiming for 19% Revenue Growth in 5 Years
Recurring Cash Flow: EQL’s core generic product delivers near‐“infinite” cash flow, thanks to its essential role in healthcare.Analysartikel • Jan 27
The Trend Of High Returns At EQL Pharma (STO:EQL) Has Us Very Interested
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analysartikel • Dec 14
EQL Pharma AB (publ)'s (STO:EQL) P/E Is Still On The Mark Following 37% Share Price Bounce
Despite an already strong run, EQL Pharma AB (publ) ( STO:EQL ) shares have been powering on, with a gain of 37% in the...Analysartikel • Nov 27
Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysartikel • Oct 29
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher
The EQL Pharma AB (publ) ( STO:EQL ) share price has done very well over the last month, posting an excellent gain of...Analysartikel • Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
EQL Pharma AB (publ)'s ( STO:EQL ) stock showed strength, with investors undeterred by its weak earnings report. We...Analysartikel • Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
The EQL Pharma AB (publ) ( NGM:EQL ) share price has done very well over the last month, posting an excellent gain of...Aktieägarnas avkastning
| EQL | SE Healthcare | SE Marknad | |
|---|---|---|---|
| 7D | -1.2% | 4.0% | 1.8% |
| 1Y | -77.9% | -5.5% | 14.1% |
Avkastning vs industri: EQL presterade sämre än Swedish Healthcare branschen som gav -5.5 % under det senaste året.
Avkastning vs Marknaden: EQL presterade sämre än Swedish marknaden som gav 14.1 % under det senaste året.
Prisvolatilitet
| EQL volatility | |
|---|---|
| EQL Average Weekly Movement | 13.2% |
| Healthcare Industry Average Movement | 6.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.3% |
Stabil aktiekurs: EQL s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för Swedish.
Volatilitet över tid: EQL s veckovolatilitet ( 13% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av Swedish aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2006 | 23 | Axel Schorling | www.eqlpharma.com |
EQL Pharma AB (publ) är verksamt inom utveckling, marknadsföring och försäljning av generiska läkemedel till apotek och sjukhus i Sverige, Danmark, Norge, Finland och övriga Europa. Bolaget erbjuder injektionsprodukter för slutenvård och beredningar för öppenvård. EQL Pharma AB (publ) bildades 2006 och har sitt säte i Lund, Sverige.
EQL Pharma AB (publ) Sammanfattning av grunderna
| EQL grundläggande statistik | |
|---|---|
| Börsvärde | SEK 600.93m |
| Vinst(TTM) | SEK 12.54m |
| Intäkter(TTM) | SEK 432.66m |
47.9x
P/E-förhållande1.4x
P/S-förhållandeÄr EQL övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| EQL resultaträkning (TTM) | |
|---|---|
| Intäkter | SEK 432.66m |
| Kostnad för intäkter | SEK 269.82m |
| Bruttovinst | SEK 162.84m |
| Övriga kostnader | SEK 150.30m |
| Intäkter | SEK 12.54m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
Aug 07, 2026
| Vinst per aktie (EPS) | 0.42 |
| Bruttomarginal | 37.64% |
| Nettovinstmarginal | 2.90% |
| Skuld/egenkapitalförhållande | 169.9% |
Hur har EQL utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/31 04:48 |
| Aktiekurs vid dagens slut | 2026/07/31 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
EQL Pharma AB (publ) bevakas av 1 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Erik Hultgård | DNB Carnegie Commissioned Research |